Targeting SIRT2 Sensitizes Melanoma Cells to Cisplatin via an EGFR-Dependent Mechanism
Related Experiment Video
Updated: Nov 3, 2025
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Iwona Karwaciak1, Anna Sałkowska2, Kaja Karaś2
1Laboratory of Transcriptional Regulation, Institute of Medical Biology, Polish Academy of Sciences, 93-232 Lodz, Poland.
Abstract:
Melanoma cells are resistant to most anticancer chemotherapeutics. Despite poor response rates and short-term efficacy, chemotherapy remains the main approach to treating this cancer. The underlying mechanisms of the intrinsic chemoresistance of melanoma remain unclear, but elucidating these mechanisms is important to improve the efficacy of chemotherapy regimens. Increasing evidence suggests that sirtuin 2 (SIRT2) plays a key role in the response of melanoma cells to chemotherapeutics; thus, in the present study, we evaluated the impact of shRNA-mediated and pharmacological inhibition of SIRT2 on the sensitivity of melanoma cells to cisplatin, which is used in several regimens to treat melanoma patients. We found that cells with SIRT2 inhibition revealed increased sensitivity to cisplatin and exhibited increased accumulation of γ-H2AX and reduced EGFR-AKT-RAF-ERK1/2 (epidermal growth factor receptor-protein B kinase-RAF kinase-extracellular signal-regulated kinase 1/2) pathway signaling compared to control cells. Thus, our results show that sirtuin 2 inhibition increased the in vitro efficacy of cisplatin against melanoma cells.
Insights
Inhibiting sirtuin 2 (SIRT2) enhances melanoma cell sensitivity to cisplatin chemotherapy. This approach increases DNA damage and reduces key cancer signaling pathways, improving treatment efficacy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Melanoma exhibits intrinsic chemoresistance, limiting the effectiveness of current chemotherapy regimens.
- Understanding chemoresistance mechanisms is crucial for developing improved melanoma treatments.
- Sirtuin 2 (SIRT2) is increasingly implicated in melanoma cell responses to chemotherapy.
Purpose of the Study:
- To investigate the effect of sirtuin 2 (SIRT2) inhibition on melanoma cell sensitivity to cisplatin.
- To elucidate the molecular mechanisms underlying SIRT2's role in chemoresistance.
Main Methods:
- Utilized shRNA-mediated and pharmacological inhibition of sirtuin 2 (SIRT2) in melanoma cells.
- Assessed melanoma cell sensitivity to cisplatin chemotherapy.
- Measured γ-H2AX accumulation and quantified signaling in the epidermal growth factor receptor-protein B kinase-RAF kinase-extracellular signal-regulated kinase 1/2 (EGFR-AKT-RAF-ERK1/2) pathway.
Main Results:
- SIRT2 inhibition significantly increased melanoma cell sensitivity to cisplatin.
- Cells with inhibited SIRT2 showed increased γ-H2AX accumulation, indicating enhanced DNA damage.
- Reduced signaling was observed in the EGFR-AKT-RAF-ERK1/2 pathway in SIRT2-inhibited cells.
Conclusions:
- Sirtuin 2 (SIRT2) inhibition enhances the in vitro efficacy of cisplatin against melanoma cells.
- Targeting SIRT2 may represent a viable strategy to overcome chemoresistance in melanoma treatment.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle